Publication details
COSYREL – lék pro pacienty s ischemickou chorobou srdeční a srdečním selháním
| Title in English | COSYREL – a drug for patients with coronary artery disease and heart failure |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue - Interní medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | hypertension; heart failure; perindopril; bisoprolol |
| Description | Fixed combinations increase the adherence/ compliance of patients to treatment and so increase the disease control. 5 basic drug groups are recommended for the treatment of hypertension and the main role plays the RAAS blockade, especially ACE inhibitors. These are combined with calcium channel blockade dihydropyridines or metabolically neutral indapamid especially in patients with metabolic syndrome. The combination with betablockers is recommended in patients with ischemic heart disease. Cosyrel is the fi rst fi xed combination of betablockers (bisoprolol fumarate) and ACE inhibitor (perindopril arginin) available on Czech market. The drug is indicated in patients with ischemic heart disease, hypertension and/ or heart failure (doses 5 mg bisoprolol/ 5 mg perindopril, 10 mg bisoprolol/ 5 mg perindopril). The combination of perindopril + betablockers decreases the primary endpoint (cardiovascular mortality, nonfatal MI a resuscitation) by 24%, fatal and nonfatal MI by 28%, hospitalisation for heart failure by 45% and all-cause mortality by 13% in the EUROPA trial. |